2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
9
Ciprofloxacin
8
Voriconazole
5
Vancomycin
4
Caspofungin
4
Amoxicillin-Potassium Clavulanate Combination
4
gamma-Globulins
3
Fluconazole
3
Filgrastim
3
Daptomycin
3
Antibiotic Prophylaxis
3
plerixafor
2
liposomal amphotericin B
2
Whole-Body Irradiation
2
Trimethoprim
2
Therapeutics
2
Sulfamethoxazole
2
Saline Solution
2
Rituximab
2
Ribavirin
2
Polymerase Chain Reaction
2
Piperacillin, Tazobactam Drug Combination
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Moxifloxacin
2
Melphalan
2
Levofloxacin
2
Lenalidomide
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Infections
×
monalizumab
×
Clear all
NCT04333914
2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2
Completed
19 enrolled